STING antagonist-3 

STING antagonist-3 is a potent STING antagonist with an IC₅₀ of 2.3 nM against human wild-type STING. STING antagonist-3 inhibits human wild-type STING and the gain-of-function STING mutants N154S and V155M. STING antagonist-3 suppresses IFN‑α2a production in stimulated human whole blood. STING antagonist-3 inhibits IP-10 production in activated human dermal microvascular endothelial cells (HMVEC-d). STING antagonist-3 can be used for the research of autoimmune diseases, autoinflammatory diseases, interferonopathies, and fibrotic disorders^[1].

STING antagonist-3 (Example 21) inhibits human wild-type STING^R232 with an IC₅₀ of 2.3 nM in the competitive HTRF binding assay^[1].
STING antagonist-3 (100 μM; temperature ramp from 15°C to 95°C over 160 cycles) stabilizes human wild-type STING protein against thermal denaturation with a ΔT_m of 29 K in the DSF assay^[1].
STING antagonist-3 (10 μM; 60 min (pre-incubation); 22 h (post-stimulation)) inhibits cGAMP-stimulated IFNα2α production in human whole blood with an IC₅₀ of 0.029 μM^[1].
STING antagonist-3 (1 h (pre-incubation); 6 h (stimulation)) inhibits dsDNA-stimulated IP-10 production in human HMVEC cells with an IC₅₀ of 6.8 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

577.72

C₃₅H₃₉N₅O₃

3106554-00-8

CC(N=C([C@@H]1CC[C@H](CC1)C(O)=O)C=C2)=C2N3C(C)=C(C(C)C)C(C4=CC=CC5=NN(C[C@H](O)C6=CC=CC=C6)C=C54)=N3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Matthias Hoffmann, et al. Heterocyclic acids as sting antagonists and the use thereof as medicament, WO, WO2025228902A1, 2025-11-06.